WO2017037539A3 - Modulation of the phospholipase a2-activating protein for treatment of myelin related diseases - Google Patents

Modulation of the phospholipase a2-activating protein for treatment of myelin related diseases Download PDF

Info

Publication number
WO2017037539A3
WO2017037539A3 PCT/IB2016/001350 IB2016001350W WO2017037539A3 WO 2017037539 A3 WO2017037539 A3 WO 2017037539A3 IB 2016001350 W IB2016001350 W IB 2016001350W WO 2017037539 A3 WO2017037539 A3 WO 2017037539A3
Authority
WO
WIPO (PCT)
Prior art keywords
phospholipase
modulation
activating protein
treatment
related diseases
Prior art date
Application number
PCT/IB2016/001350
Other languages
French (fr)
Other versions
WO2017037539A2 (en
Inventor
Tzipora C. FALIK ZACCAI
Original Assignee
The Health Corporation Of The Galilee Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Health Corporation Of The Galilee Medical Center filed Critical The Health Corporation Of The Galilee Medical Center
Publication of WO2017037539A2 publication Critical patent/WO2017037539A2/en
Publication of WO2017037539A3 publication Critical patent/WO2017037539A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

The present invention provides a method of treating a subject afflicted with a white matter disorder comprising administering to the subject an agent that induces the activity of the Phospholipase A2-Activating Protein (PLAA) pathway in the subject.
PCT/IB2016/001350 2015-09-02 2016-09-02 Modulation of the phospholipase a2-activating protein for treatment of myelin related diseases WO2017037539A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562213339P 2015-09-02 2015-09-02
US62/213,339 2015-09-02

Publications (2)

Publication Number Publication Date
WO2017037539A2 WO2017037539A2 (en) 2017-03-09
WO2017037539A3 true WO2017037539A3 (en) 2017-04-27

Family

ID=58186946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/001350 WO2017037539A2 (en) 2015-09-02 2016-09-02 Modulation of the phospholipase a2-activating protein for treatment of myelin related diseases

Country Status (1)

Country Link
WO (1) WO2017037539A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625125A (en) * 1994-08-09 1997-04-29 Dnx Biotherapeutics Phospholipase A2 expressing transgenic animals
US20140199693A1 (en) * 2011-03-18 2014-07-17 Stichting Vu-Vumc Method of analysing a blood sample of a subject for the presence of a disease marker

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625125A (en) * 1994-08-09 1997-04-29 Dnx Biotherapeutics Phospholipase A2 expressing transgenic animals
US20140199693A1 (en) * 2011-03-18 2014-07-17 Stichting Vu-Vumc Method of analysing a blood sample of a subject for the presence of a disease marker

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ESAKI ET AL.: "Dual roles of PGE2- EP 4 signaling in mouse experimental autoimmune encephalomyelitis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 27, 21 June 2010 (2010-06-21), pages 12233 - 12238, XP055376612 *
KALYVAS ET AL.: "Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis", BRAIN, vol. 132, 13 February 2009 (2009-02-13), pages 1221 - 1235, XP055376627 *
KUWATA ET AL.: "Cytosolic phospholipase A2 is required for cytokine-induced expression of type IIA secretory phospholipase A2 that mediates optimal cyclooxygenase-2-dependent delayed prostaglandin E2 generation in rat 3Y1 fibroblasts", J BIOL CHEM, vol. 273, no. 3, 16 January 1998 (1998-01-16), pages 1733 - 1740, XP055376616 *
MULLALLY ET AL.: "Doa1 is a Cdc48 adapter that possesses a novel ubiquitin binding domain", MOLECULAR AND CELLULAR BIOLOGY, vol. 26, no. 3, 1 February 2006 (2006-02-01), pages 822 - 830, XP055376618 *
SUN ET AL.: "miR-203 regulates nociceptive sensitization after incision by controlling phospholipase A2 activating protein expression", ANESTHESIOLOGY, vol. 117, no. 3, 1 September 2012 (2012-09-01), pages 626 - 638, XP055376625 *
ZHANG ET AL.: "Alteration in the activation state of new inflammation-associated targets by phospholipase A2-activating protein (PLAA)", CELL SIGNAL, vol. 20, no. 5, 17 January 2008 (2008-01-17), pages 844 - 861, XP055376614 *

Also Published As

Publication number Publication date
WO2017037539A2 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
WO2017134302A3 (en) Targeted therapeutic agents and uses thereof
MX2023000049A (en) Methods of conditioning patients for t cell therapy.
EA201890725A1 (en) PHARNESIDE X-RECEPTOR AGONISTS AND THEIR APPLICATION
MX2021000071A (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease.
MX2017005258A (en) Combination therapy for treatment of disease.
MX2017008844A (en) Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease.
GB2541571A (en) Pharmaceutical compositions
EP3180009A4 (en) Zoledronic acid dosage forms for the treatment of pain
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201790575A1 (en) TRIAZOLOPIRASINONS AS PDE1 INHIBITORS
MX2017016134A (en) Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease.
GEP20217317B (en) Combination therapy for the treatment of cancer
EA201792157A1 (en) IMIDAZOPIRASINONS AS PDE1 INHIBITORS
EP3313517A4 (en) Histotripsy therapy systems and methods for the treatment of brain tissue
PH12018500578A1 (en) Methods of treating inflammatory diseases
MA40364A (en) Combination therapy for treatment of cancer
PH12018502154A1 (en) Methods of treating ocular conditions
WO2018029656A3 (en) Methods for making and using therapeutic exosomes
MX2017014456A (en) Therapeutic uses of l-4-chlorokynurenine.
EA201691567A1 (en) METHODS OF TREATING PULMONARY INJURIES TO THE BRAIN
MY195000A (en) Method for the treatment of neurological disease
MX2022006862A (en) Dual magl and faah inhibitors.
EA201692402A1 (en) MEDICAL FORMS FOR LOCAL APPLICATION AND THEIR USE
PH12017500602A1 (en) Methods for treating ocular conditions
MX2017010654A (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16840898

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16840898

Country of ref document: EP

Kind code of ref document: A2